Identification of Novel Natural BACE1 Inhibitors for Alzheimer's Disease via In Silico Approach
Abstract
Background: Alzheimer's disease (AD) is a neurological ailment that causes progressive memory loss as neurons die. Beta-secretase 1 (BACE1) is a key enzyme in the production of amyloid beta, which is a characteristic of Alzheimer's disease. Developing new BACE1 inhibitors with no cytotoxicity is a promising method to treat AD.
Methods: The goal of this study was to find new BACE1 inhibitors by screening natural compounds in the ZINC database against the BACE1 active site. The compounds were screened against BACE1 using the PyRx 0.8 program. The SwissADME web server was used to determine the ADMET properties of hit compounds.
Results: The hit compounds ZINC3875408, ZINC4098603, ZINC95561079, ZINC299817515, and ZINC67903362 exhibited higher binding affinities to BACE1 than the control compound AZD3293. The Asp32, Lys224, Tyr198, Thr329, Ile226, Val332, Arg128, Tyr71, Phe108, Lys107, Gly74, Gly13, Gly11, Gln12, Ile110, Trp115, Leu30, and Gly230 were the important binding residues of BACE1 protein with these compounds as well as the control compound. These compounds also have good drug-like qualities.
Conclusion: The compounds ZINC3875408, ZINC4098603, ZINC95561079, ZINC299817515, and ZINC67903362 can be used as BACE1 inhibitors to manage AD. However, experimental validation is needed to optimize these compounds as BACE1 inhibitors.
Keywords: Alzheimer's Disease; Amyloid Beta; Beta-Secretase 1; Natural Compounds
Full Text:
PDFReferences
Peeri Alloul K, Sauriol L, Kennedy W, Laurier C, Tessier G, et al. Alzheimer's disease: a review of the disease, its epidemiology and economic impact. Archives of Gerontology and Geriatrics, (1998); 27(3): 189-221.
Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimer's Research & Therapy, (2017); 9(1): 71.
Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules, (2020); 25(24): 5789.
Madnani RS. Alzheimer’s disease: A mini-review for the clinician. Frontiers in Neurology, (2023); 14: 1178588.
Buccellato FR, D’Anca M, Fenoglio C, Scarpini E, Galimberti D. Role of oxidative damage in alzheimer’s disease and neurodegeneration: From pathogenic mechanisms to biomarker discovery. Antioxidants, (2021); 10(9): 1353.
Pepeu G, Giovannini MG. The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Research, (2017); 1670: 173-184.
Vecchio I, Sorrentino L, Paoletti A, Marra R, Arbitrio M. The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease. Journal of Central Nervous System Disease, (2021); 13: 11795735211029113.
Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer’s disease. Neural Regeneration Research, (2022); 17(3): 543-549.
Taylor HA, Przemylska L, Clavane EM, Meakin PJ. BACE1: More than just a beta-secretase. Obesity Reviews, (2022); 23(7): e13430.
Sabe VT, Ntombela T, Jhamba LA, Maguire GE, Govender T, et al. Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. European Journal of Medicinal Chemistry, (2021); 224: 113705.
Yu W, MacKerell AD, Jr. Computer-Aided Drug Design Methods. Methods in Molecular Biology, (2017); 1520: 85-106.
Kalyaanamoorthy S, Chen YP. Structure-based drug design to augment hit discovery. Drug Discovery Today, (2011); 16(17-18): 831-839.
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2014): 243-250.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, (2017); 7: 42717.
Huang HJ, Lee CC, Chen CY. In silico design of BACE1 inhibitor for Alzheimer's disease by traditional Chinese medicine. BioMed Research International, (2014); 2014: 741703.
Korshavn KJ, Satriano C, Lin Y, Zhang R, Dulchavsky M, et al. Reduced lipid bilayer thickness regulates the aggregation and cytotoxicity of amyloid-beta. Journal of Biological Chemistry, (2017); 292(11): 4638-4650.
Kotler SA, Walsh P, Brender JR, Ramamoorthy A. Differences between amyloid-beta aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease. Chemical Society Reviews Journal, (2014); 43(19): 6692-6700.
Rajasekhar K, Narayanaswamy N, Murugan NA, Kuang G, Agren H, Govindaraju T. A high affinity red fluorescence and colorimetric probe for amyloid beta aggregates. Scientific Reports, (2016); 6: 23668.
Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, et al. AZD3293: Pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer's disease. Journal of Alzheimer's Disease, (2017); 55(3): 1039-1053.
Butini S, Brogi S, Novellino E, Campiani G, Ghosh AK, et al. The structural evolution of beta-secretase inhibitors: a focus on the development of small-molecule inhibitors. Current Topics in Medicinal Chemistry, (2013); 13(15): 1787-1807.
Oehlrich D, Prokopcova H, Gijsen HJ. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorganic & Medicinal Chemistry Letters, (2014); 24(9): 2033-2045.
Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, (2011); 7(2): 146-157.
Shaikh S, Aaqil H, Rizvi SM, Shakil S, Abuzenadah AM, et al. Comparative inhibition study of compounds identified in the methanolic extract of Apamarga kshara against trichomonas vaginalis carbamate kinase (TVCK): an enzoinformatics approach. Interdisciplinary Sciences: Computational Life, (2016); 8(4): 357-365.
DOI: http://dx.doi.org/10.62940/als.v12i2.3519
Refbacks
- There are currently no refbacks.